Goldman Sachs’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Goldman Sachs’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30,366	Closed	–	–	6070
2024 Q1	$0	Buy	30,366 +13,384	+79%	+$53.8K	﹤0.01%	6004
2023 Q4	$68.8K	Buy	+16,982	New	+$51.8K	﹤0.01%	5345
2023 Q3	–	Sell	-28,941	Closed	-$270K	–	5969
2023 Q2	$270K	Buy	+28,941	New	+$285K	﹤0.01%	5060

Goldman Sachs's THRX Position: Q2 2024 in Review

Goldman Sachs sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q2 2024, closing a stake of 30,366 shares.

Goldman Sachs first reported a position in THRX in Q2 2023 and held it in 3 quarters. The position peaked at $270K in Q2 2023. 0 funds tracked by Wall St. Rank hold THRX as of Q2 2024.

Goldman Sachs reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Goldman Sachs sold 30,366 Theseus Pharmaceuticals, Inc. Common Stock shares in Q2 2024.
Goldman Sachs first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 3 quarters.
Goldman Sachs's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $270K in Q2 2023.
0 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.